ArticleInternational journal of chronic obstructive pulmonary disease2026
Afebrile Presentation in COPD Patients with Influenza A: A Risk Factor for Prolonged Viral Shedding.
Article in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate the risk factors for prolonged viral shedding in influenza A patients treated with oseltamivir and analyze fever patterns in chronic obstructive pulmonary disease (COPD) patients. Patients and Methods: This retrospective study analyzed 309 hospitalized patients with RT-PCR-confirmed influenza A at a multi-campus tertiary medical center from 2022 to 2025. Influenza A virus retesting was performed on day 6 of antiviral treatment to assess viral clearance. Multivariate logistic regression was used to identify risk factors for prolonged viral shedding. ROC curve analysis evaluated the predictive value of absolute lymphocyte count (ALC). Subgroup analyses compared fever patterns in COPD and non-COPD patients using the Mann-Whitney U and chi-square (χ Results: Overall, 309 influenza A inpatients were included. Six independent risk factors for prolonged viral shedding were identified: older age (95% CI 1.01-1.05), lymphopenia (95% CI 0.09-0.38), cerebrovascular disorders (95% CI 1.64-16.08), immunosuppressants (95% CI 1.05-3.36), delayed antiviral treatment (95% CI 4.13-15.27), and fungal coinfection (95% CI 1.25-4.69). Notably, 63.7% of the COPD patients were afebrile, compared to 23.6% of non-COPD patients (p < 0.05). In the COPD group, prolonged shedders had higher odds of afebrile status (95% CI 1.39-12.59), lower ALC (95% CI 0.01-0.17) and delayed oseltamivir initiation (95% CI 1.65-13.28) than nonprolonged shedders. The ALC demonstrated good predictive accuracy for prolonged viral shedding (AUC 0.75 overall; AUC 0.77 for the COPD group). Conclusion: Early antiviral therapy and targeted management for high-risk groups (especially COPD patients) are valuable. Afebrile presentations in COPD patients highlight the importance of routine influenza testing during exacerbations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.